EGFR and neoplasm: This protein had already been described as a regulator of both epidermal growth factor receptor (EGFR) activity and programmed death-ligand 1 (PD-L1 or CD 274) surface marker, indicating its involvement or regulatory capability in tumor-mediated immunosuppression [136,137], with its use as a biomarker being pointed out in other tumors, such as oral squamous cell carcinoma [138] or colorectal carcinoma, among others [137].